Coronary Artery Bypass Graft Market Overview
The Coronary Artery Bypass Graft Market is expanding as the prevalence of multivessel coronary artery disease increases and healthcare systems invest in advanced cardiac surgery technologies. Aging populations, demand for complete revascularization, adoption of minimally invasive and robotic-assisted procedures, and improvements in cardiac surgery infrastructure are supporting market growth.
According to the Market Research Future report updated September 15, 2026, the global Coronary Artery Bypass Graft Market was valued at USD 18.65 Billion in 2025 and is projected to grow from USD 19.74 Billion in 2026 to USD 32.93 Billion by 2035, registering a CAGR of 5.85% during 2026–2035. North America led the market with approximately 39.0% share in 2025, while Asia-Pacific is the fastest-growing region with a projected CAGR of 7.6%. On-pump CABG accounted for 58.2% of revenue, heart positioners and tissue stabilizers represented 28.5% of product sales, and hospitals accounted for 68.4% of the end-user segment in 2025.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.marketresearchfuture.com/sample_request/2285
Key players driving innovation and competitiveness in the Coronary Artery Bypass Graft Market include:
Medtronic plc
Getinge AB
LivaNova PLC
Terumo Corporation
Abbott Laboratories
Teleflex Incorporated
Edwards Lifesciences
Boston Scientific
Karl Storz SE
Intuitive Surgical
The market is being shaped by the rising burden of multivessel coronary artery disease, aging populations, advances in minimally invasive cardiac surgery, robotic-assisted platforms, and changes in healthcare reimbursement. Hospitals are increasingly exploring technologies that can support shorter recovery periods, improved procedural efficiency, and better patient outcomes. Bundled-payment and value-based reimbursement models are also encouraging healthcare providers to focus on complete revascularization and post-operative outcomes.
The Coronary Artery Bypass Graft Market can be segmented by Procedure Type into On-Pump CABG, Off-Pump CABG, and Minimally Invasive & Robotic CABG. By Product and Services, it includes Heart Positioners & Tissue Stabilizers, Cardiopulmonary Bypass Machines, Endoscopic Vessel-Harvesting Systems, and Cannulae & Perfusion Accessories. By Graft or Conduit Material, it covers Saphenous Vein Grafts, Internal Mammary Artery Grafts, Radial Artery Grafts, and Synthetic & Bio-Engineered Grafts. By Surgery Complexity, it includes Single Bypass, Double Bypass, Triple Bypass, and Quadruple-and-Higher Bypass. By End User, it covers Hospitals, Ambulatory Surgical Centers, and Cardiac Specialty Centers.
The growing need for advanced cardiac surgery is creating opportunities for medical-device manufacturers, cardiac hospitals, surgical technology companies, robotic platform developers, and providers of graft and perfusion technologies. Robotic total arterial revascularization, endoscopic vessel harvesting, AI-supported surgical planning, synthetic and bio-engineered grafts, and outcome-linked service models can support future market development.
Recent Developments and Market Trends:
On-pump CABG remains the dominant procedure type with 58.2% revenue share in 2025, supported by its continued use in complex multivessel cardiac procedures.
Minimally invasive and robotic-assisted CABG is projected to grow at a 10.1% CAGR through 2035 as hospitals invest in technologies designed to support reduced recovery times and improved procedural efficiency.
Heart positioners and tissue stabilizers represent the largest product category with 28.5% share in 2025 because they are used across both on-pump and off-pump procedures.
Endoscopic vessel-harvesting systems are projected to record an 8.8% CAGR through 2035 as healthcare providers seek technologies that can support less invasive vessel harvesting and recovery.
Saphenous vein grafts accounted for 66.1% of the graft and conduit material segment in 2025, supported by their broad availability and established use in CABG procedures.
Synthetic and bio-engineered grafts are projected to grow at a 9.3% CAGR through 2035 as research advances toward off-the-shelf vascular graft solutions.
Triple bypass procedures represented 32.7% of the surgery-complexity segment in 2025, reflecting the prevalence of three-vessel coronary artery disease.
Quadruple-and-higher bypass procedures are projected to grow at a 10.0% CAGR through 2035, supported by increasing demand for treatment of complex and diffuse coronary disease.
Hospitals accounted for 68.4% of the end-user segment in 2025 because CABG procedures require specialized cardiac surgery teams, intensive-care infrastructure, and post-operative monitoring.
Ambulatory Surgical Centers are projected to experience an 8.1% CAGR through 2035 as minimally invasive techniques support the expansion of selected lower-risk cardiac procedures into alternative care settings.
North America represented 39.0% of global revenue in 2025, supported by established cardiac surgery centers, reimbursement infrastructure, and investment in advanced surgical technologies.
Asia-Pacific is projected to be the fastest-growing regional market at a 7.6% CAGR through 2035, supported by rising cardiovascular disease prevalence, expanding cardiac-care infrastructure, and government investment in hospitals.
Recent industry developments include Medtronic’s FDA 510(k) clearance for its Hugo RAS cardiac surgery module for internal mammary artery harvesting, expansion of the U.S. BPCI-A model to additional hospitals, Terumo’s acquisition of NovaBiomedical’s perfusion monitoring division, and updated European Medical Device Regulation implementing rules affecting Class III cardiac surgical devices.
Reasons to Buy the Report:
Provides comprehensive insights into the Coronary Artery Bypass Graft Market dynamics, trends, opportunities, and growth potential.
Helps identify opportunities across on-pump, off-pump, minimally invasive, and robotic CABG procedures.
Offers detailed segmentation analysis across procedure type, products and services, graft materials, surgery complexity, end user, and geographic markets.
Includes competitive intelligence covering leading cardiac surgery, perfusion, vascular, surgical robotics, and medical-device companies.
Supports informed business decisions using market forecasts, cardiovascular disease trends, cardiac surgery infrastructure, reimbursement developments, minimally invasive technologies, and regional opportunities.
Future Outlook:
The future of the Coronary Artery Bypass Graft Market will be shaped by the rising prevalence of multivessel coronary artery disease, population aging, minimally invasive surgery, robotic-assisted platforms, advanced graft technologies, and outcome-focused healthcare models. Market Research Future projects the market to reach USD 32.93 Billion by 2035 at a CAGR of 5.85%.
On-pump CABG should remain an important procedure segment, while Minimally Invasive & Robotic CABG is positioned for strong growth as hospitals expand their investment in robotic and advanced surgical platforms. Heart Positioners & Tissue Stabilizers should continue to represent a major product category, while Endoscopic Vessel-Harvesting Systems are expected to gain adoption.
Saphenous Vein Grafts should remain widely used, while Synthetic & Bio-Engineered Grafts are expected to experience increasing interest as vascular tissue engineering advances. Triple bypass procedures should remain an important surgery-complexity category, while more complex quadruple-and-higher procedures are projected to grow strongly.
Hospitals should continue to represent the largest end-user segment, while Ambulatory Surgical Centers and specialized cardiac facilities may gain importance as minimally invasive procedures and alternative care pathways expand. North America should retain its leading position, while Asia-Pacific is expected to provide significant growth opportunities through expanding cardiac-care infrastructure and increasing cardiovascular disease burden.
➤➤Explore Our Latest Related Reports:
